← Amalgamated Financial Corp.
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Net income | $44.7m | $47.2m | $46.2m | $52.9m | $81.5m | $88.0m | $106.4m | $104.4m | |
| Depreciation and amortization | $4.2m | $4.6m | $6.2m | $3.6m | $3.5m | $3.5m | $4.7m | $6.2m | |
| Amortization of intangible assets | $969k | $1.4m | $1.4m | $1.2m | $1.0m | $888k | $730k | $574k | |
| Deferred income tax expense | $4.7m | $5.0m | ($407k) | $7.0m | $14.4m | $4.2m | $5.2m | $1.7m | |
| Net (income) loss from equity method investments | $0 | $0 | ($7.4m) | ($150k) | $2.8m | ($4.9m) | $831k | $1.7m | |
| Decrease (increase) in equity method investments | — | — | — | — | ($7.4m) | ($757k) | $1.9m | ($6.5m) | |
| Provision for credit losses | — | — | — | ($287k) | $15.0m | $14.7m | $10.3m | $16.3m | |
| Stock-based compensation expense | $920k | $2.4m | $2.4m | $1.8m | $2.7m | $4.7m | $5.5m | $6.9m | |
| Net loss on sale of securities available for sale and other assets | $249k | ($83k) | ($1.6m) | ($649k) | $3.6m | $7.4m | $9.7m | $3.4m | |
| Net (gain) loss on sale of loans and change in fair value on loans held-for-sale | $451k | ($13k) | ($2.5m) | ($1.9m) | $610k | ($32k) | $8.2m | $2.7m | |
| Net gain on death benefits of bank-owned life insurance | $0 | $0 | ($1.6m) | ($266k) | ($1.9m) | ($613k) | $0 | ($562k) | |
| Proceeds from sales of loans held for sale | $4.1m | $21.0m | $159.3m | $123.6m | $28.4m | $17.8m | $22.1m | $29.0m | |
| Originations of loans held for sale | $0 | ($22.5m) | ($165.6m) | ($112.8m) | ($8.4m) | ($14.6m) | ($21.7m) | ($30.1m) | |
| Increase in accrued interest receivable | — | — | — | — | ($12.6m) | ($14.0m) | ($5.7m) | ($4.0m) | |
| Decrease (increase) in other assets | ($16.6m) | $18.2m | $11.0m | $7.4m | $19.1m | $11.7m | ($2.4m) | ($856k) | |
| Increase (decrease) in other liabilities | ($8.8m) | $12.4m | ($4.1m) | ($11.1m) | ($5.8m) | $181k | ($16.2m) | $778k | |
| Net increase in loans | ($94.7m) | ($350.3m) | ($36.6m) | $167.5m | ($826.3m) | ($317.2m) | ($360.2m) | ($342.0m) | |
| Proceeds from sales of loans | $4.2m | $115.9m | $0 | $0 | $0 | $0 | $36.6m | $73.2m | |
| Purchase of securities available for sale | ($595.3m) | ($479.3m) | ($683.7m) | ($1.2b) | ($678.9m) | ($116.5m) | ($824.5m) | ($965.0m) | |
| Purchase of securities held-to-maturity | ($2.0m) | ($291.6m) | ($256.1m) | ($472.6m) | ($584.9m) | ($264.5m) | ($92.2m) | ($158.0m) | |
| Proceeds from sales of securities available for sale | $125.4m | $245.3m | $94.7m | $111.3m | $249.9m | $285.4m | $394.1m | $364.8m | |
| Maturities, principal payments and redemptions of securities available for sale | $250.0m | $205.6m | $278.5m | $508.2m | $325.6m | $167.8m | $310.8m | $477.9m | |
| Maturities, principal payments and redemptions of securities held-to-maturity | $7.5m | $9.0m | $52.8m | $119.8m | $139.3m | $108.9m | $204.3m | $190.9m | |
| Decrease (increase) in resell agreements | $0 | $0 | ($154.8m) | ($74.2m) | $203.3m | ($24.2m) | $26.3m | ($24.9m) | |
| Decrease (increase) in FHLBNY stock, net | $15.1m | $147k | $3.1m | $214k | ($25.9m) | $25.2m | ($11.3m) | $10.7m | |
| Purchases of premises and equipment, net | ($1.4m) | ($753k) | ($1.6m) | ($2.4m) | ($1.7m) | ($1.5m) | ($1.8m) | ($1.4m) | |
| Proceeds from redemption of bank-owned life insurance | $0 | $0 | $2.9m | $1.0m | $4.2m | $2.9m | $0 | $2.2m | |
| Proceeds from sale of owned assets | $0 | $0 | $1.6m | $0 | $0 | $0 | $0 | $46k | |
| Net increase in deposits | $510.3m | $535.7m | $697.7m | $1.0b | $238.8m | $417.0m | $168.6m | $768.6m | |
| Increase (decrease) in other borrowings, net | — | — | — | $0 | $580.0m | ($345.6m) | $16.3m | ($244.9m) | |
| Redemption of AREMCO class B shares | ($7.0m) | $0 | ($5k) | $0 | $0 | $0 | ($152k) | $0 | |
| Right-of-use assets obtained in exchange for lease liabilities | $0 | $55.8m | $777k | $0 | $2.3m | $0 | $560k | $2.9m | |
| Loans transferred from held-for-sale | — | — | — | $1.0m | $25.3m | $4.7m | $0 | $2.5m | |
| Loans transferred to held-for-sale | — | $2.3m | $8.8m | $1.0m | $25.3m | $3.6m | $81.6m | $42.5m | |
| Cumulative change due to adoption of ASU No. 2016-13 | — | — | — | $0 | $0 | $17.8m | $0 | $0 | |
| Net cash provided by operating activities | $31.0m | $83.5m | $65.8m | $70.5m | $147.3m | $117.2m | $124.1m | $135.8m | |
| Net cash used in investing activities | ($258.3m) | ($545.9m) | ($755.1m) | ($865.4m) | ($1.2b) | ($134.4m) | ($315.9m) | ($378.0m) | |
| Net gain on repurchase of subordinated debt | — | — | $0 | $0 | ($617k) | ($1.4m) | ($1.1m) | $0 | |
| Repurchase of subordinated debt | — | $0 | $0 | $83.8m | ($5.6m) | ($6.0m) | ($5.9m) | $0 | |
| Common stock issued under Equity Program | $0 | $0 | $0 | $0 | $665k | $804k | $789k | $1.4m | |
| Repurchase of common stock | $0 | ($5.8m) | ($7.0m) | ($2.9m) | ($12.5m) | ($8.3m) | ($1.1m) | ($32.3m) | |
| Payments related to repurchase of common stock for equity awards | — | — | — | ($1.9m) | ($1.9m) | ($1.2m) | ($2.2m) | ($2.8m) | |
| Dividends paid on common stock | ($1.9m) | ($8.3m) | ($10.0m) | ($10.0m) | ($11.2m) | ($12.3m) | ($14.2m) | ($17.2m) | |
| Net cash provided by financing activities | $191.7m | $504.1m | $605.6m | $1.1b | $788.2m | $44.2m | $162.1m | $472.7m | |
| Increase in cash surrender value of bank-owned life insurance | ($853k) | ($1.6m) | ($1.5m) | ($2.1m) | ($2.0m) | ($2.3m) | ($2.5m) | ($2.6m) | |
| Increase (decrease) in cash, cash equivalents, and restricted cash | ($35.6m) | $41.7m | ($83.8m) | $291.7m | ($266.9m) | $27.0m | ($29.8m) | $230.5m | |
| Cash, cash equivalents, and restricted cash at beginning of year | $80.8m | $122.5m | $38.8m | $330.5m | $63.5m | $90.6m | $60.7m | $291.2m | |
| Interest paid during the year | $14.6m | $19.0m | $11.5m | $6.0m | $18.0m | $85.7m | $128.8m | $124.4m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.